Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

What is the efficacy and safety of lutikizumab, a dual-variable domain interleukin (IL) 1α/1β antagonist, for adults with moderate to severe hidradenitis suppurativa (HS) who experienced anti–tumor necrosis factor therapy failure?In this phase 2, double-blind, placebo-controlled randomized clinical trial of 153 patients with HS, participants who received lutikizumab, 300 mg, every week or every other week showed improvements vs placebo across key assessed outcomes. Serious adverse events were reported for 2 of 39 participants treated with lutikizumab, 300 mg, every week (5.1%); 2 of 37 participants treated with lutikizumab, 300 mg, every other week (5.4%); and 1 of 40 placebo-treated participants (2.5%).These initial data from this phase 2 randomized clinical trial suggest that dual inhibition of IL-1α and IL-1β by lutikizumab improved the signs and symptoms associated with HS and support further clinical development of lutikizumab in HS.

Corresponding Author: Alexa B. Kimball, MD, MPH, 330 Brookline Ave, Boston, MA 02215 (clears@bidmc.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.